This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 11-14, 2026
Hynes Convention CenterBoston, MA
Book Now
Menu
Book
keyboard_arrow_right

Main Conference - Day 2 (May 13)

keyboard_arrow_leftSearch & Filter
search
Main Conference - Day 2 (May 13)
search
Concurrent Tracks
Showing 1 of 1 Streams
8:25am - 8:30am
Chairman’s Remarks
  • Cecilia Fernández, Ph.D. - Entrepreneur in Residence, Mass General Brigham Ventures
8:30am - 9:00am
Transformative LDL Cholesterol Lowering In Vivo CRISPR Gene Editing Approach for Hyperlipidemia and Atherosclerotic Cardiovascular Disease
  • Linda Burkly - Executive Vice President & Chief Scientific Office, Editas Medicine
9:00am - 9:30am
Toward In Vivo Genetic Medicines with Site-specific Integration of Therapeutically Relevant Genes Via an RNA-only Platform
  • Ari Friedland - Vice President of Research, Typewriter Therapeutics
9:30am - 10:00am
Development of Bespoke Genome Editing Technologies to Treat Disease
  • Ben Kleinstiver, PhD - Associate Professor, Massachusetts General Hospital & Harvard Medical School
Showing 1 of 1 Streams
10:45am - 11:15am
Applying Machine Learning to Identify Differentiated Target Mechanisms and Design Next-Generation Oligonucleotide Therapeutics
  • Greg Hoffman, PhD - Chief Scientific Officer, Deep Genomics
11:15am - 11:45am
Delivery of Gene Writers to Hematopoetic Stem Cells towards an In Vivo Therapy for Sickle Cell Disease
  • Jane Wang, PhD - VP and Head of Delivery and Process Devlopment, Tessera Therapeutics
11:45am - 12:15pm
Late Breaking Presentation
12:15pm - 12:20pm
Transition to Spotlight Presentation Rooms
Concurrent Tracks
Showing 1 of 1 Streams
1:55pm - 2:00pm
Co-Chairs' Remarks
  • Seth Alexander, PhD - Director of RNA Technologies, Prime Medicine
  • Bradley Pentelute, PhD - Professor, Chemistry, Massachusetts Institute of Technology
2:00pm - 2:30pm
Efficient Modification Chemistry for RNA Stabilization and Control
  • Eric Kool, Ph.D - Professor of Chemistry, Stanford University
2:30pm - 3:00pm
Beyond Codons: The Structural and Regulatory Logic Governing mRNA Translation
  • Devan Shah - Founder & Chief Executive Officer, RNAV8 Bio
3:00pm - 3:30pm
Analytical Platform Technologies for mRNA-based Therapeutics and Vaccines
  • Andreas Kuhn, PhD - Senior Vice President RNA Biochemistry & CMC Development, BioNTech SE
Showing 1 of 1 Streams
4:15pm - 4:45pm
Self-replicating RNA (srRNA) Vaccines Using Unmodified Bases Show An Expanded Clinical Therapeutic Index and Sustained Immune Responses
  • Andrew Geall, PhD - Co-founder and Chief Development Officer, Replicate Bioscience
4:45pm - 5:15pm
Process and Technology Innovation for RNA Therapeutics
  • Telmo Graça, PhD - Head of mRNA Process Development, Lonza
5:15pm - 5:45pm
Enabling Next-Generation mRNA Therapeutics Through a Cell-Based mRNA Design and Manufacturing Platform
  • Marian Kupculak, PhD - Co-Founder and Chief Science Officer, Sensible Biotechnologies
Main Conference - Day 1 Keynote Sessions (May 12)
NextMain Conference - Day 3 (May 14)
Filter
Free / Premium
Streams
Clear
Choose Day